Language:

Addressing dyslipidemic risk beyond LDL-cholesterol

The Journal of clinical investigation, 2022-01, Vol.132 (1), p.1-10 [Peer Reviewed Journal]

COPYRIGHT 2022 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Jan 2022 ;2022 Tall et al. 2022 Tall et al. ;ISSN: 1558-8238 ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/JCI148559 ;PMID: 34981790

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Addressing dyslipidemic risk beyond LDL-cholesterol
Author: Tall, Alan R ; Thomas, David G ; Gonzalez-Cabodevilla, Ainara G ; Goldberg, Ira J
Subjects: Angiopoietin ; Angiopoietin-Like Protein 3 - antagonists & inhibitors ; Angiopoietin-Like Protein 3 - genetics ; Angiopoietin-Like Protein 3 - metabolism ; Animals ; Antisense RNA ; Antisense therapy ; Apolipoprotein C-III - antagonists & inhibitors ; Apolipoprotein C-III - genetics ; Apolipoprotein C-III - metabolism ; Apolipoproteins ; Arteries ; Arteriosclerosis ; Atherosclerosis ; Atherosclerosis - blood ; Atherosclerosis - drug therapy ; Atherosclerosis - genetics ; Cardiovascular disease ; Cardiovascular diseases ; Cholesterol ; Cholesterol, LDL ; Cholesterol, LDL - blood ; Cholesterol, LDL - genetics ; Clinical trials ; Diabetes ; Dyslipidemia ; Dyslipidemias ; Dyslipidemias - blood ; Dyslipidemias - drug therapy ; Dyslipidemias - genetics ; Fish oils ; Foam Cells - metabolism ; Genetic variance ; Genetic Variation ; Health aspects ; Heart attacks ; High density lipoprotein ; Humans ; Hypertension ; Lipid metabolism ; Lipids ; Lipolysis ; Lipoproteins ; Lipoproteins, HDL - blood ; Lipoproteins, HDL - genetics ; Low density lipoprotein ; Metabolic syndrome ; Metabolic Syndrome - blood ; Metabolic Syndrome - drug therapy ; Metabolic Syndrome - genetics ; Mortality ; Obesity ; Obesity - blood ; Obesity - drug therapy ; Obesity - genetics ; Patients ; Review Series ; Risk factors ; RNA-mediated interference ; Statins ; Weight control
Is Part Of: The Journal of clinical investigation, 2022-01, Vol.132 (1), p.1-10
Description: Despite the success of LDL-lowering drugs in reducing cardiovascular disease (CVD), there remains a large burden of residual disease due in part to persistent dyslipidemia characterized by elevated levels of triglyceride-rich lipoproteins (TRLs) and reduced levels of HDL. This form of dyslipidemia is increasing globally as a result of the rising prevalence of obesity and metabolic syndrome. Accumulating evidence suggests that impaired hepatic clearance of cholesterol-rich TRL remnants leads to their accumulation in arteries, promoting foam cell formation and inflammation. Low levels of HDL may associate with reduced cholesterol efflux from foam cells, aggravating atherosclerosis. While fibrates and fish oils reduce TRL, they have not been uniformly successful in reducing CVD, and there is a large unmet need for new approaches to reduce remnants and CVD. Rare genetic variants that lower triglyceride levels via activation of lipolysis and associate with reduced CVD suggest new approaches to treating dyslipidemia. Apolipoprotein C3 (APOC3) and angiopoietin-like 3 (ANGPTL3) have emerged as targets for inhibition by antibody, antisense, or RNAi approaches. Inhibition of either molecule lowers TRL but respectively raises or lowers HDL levels. Large clinical trials of such agents in patients with high CVD risk and elevated levels of TRL will be required to demonstrate efficacy of these approaches.
Publisher: United States: American Society for Clinical Investigation
Language: English
Identifier: ISSN: 1558-8238
ISSN: 0021-9738
EISSN: 1558-8238
DOI: 10.1172/JCI148559
PMID: 34981790
Source: Geneva Foundation Free Medical Journals at publisher websites
AUTh Library subscriptions: ProQuest Central
MEDLINE
PubMed Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Addressing dyslipidemic risk beyond LDL-cholesterol

COPYRIGHT 2022 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Jan 2022 ;2022 Tall et al. 2022 Tall et al. ;ISSN: 1558-8238 ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/JCI148559 ;PMID: 34981790

Searching Remote Databases, Please Wait